Resources from the same session
67O - Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
68O - Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)
Presenter: Do-Youn Oh
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 67O and 68O
Presenter: Sebastian Stintzing
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Slides
Webcast
Q&A and discussion
Presenter: Eric Van Cutsem
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Slides
Webcast
69O - First-line serplulimab versus placebo in combination with chemotherapy in PD-L1-positive oesophageal squamous cell carcinoma (ASTRUM-007): A randomised, double-blind, multicentre phase III study
Presenter: Jing Huang
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
70O - Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
Presenter: Ken Kato
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Presenter: Eric Van Cutsem
Session: Proffered Paper session: Gastrointestinal tumours
Resources:
Slides
Webcast